Atai Beckley Inc.

NEW YORK, July 16, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating AtaiBeckley Inc. (NASDAQ: ATAI ) related to its sale to Eli Lilly and Company.

prnewswire.com - 2026-07-16 14:23:00

AtaiBeckley (ATAI) shares are ripping higher on Thursday morning after pharmaceutical giant Eli Lilly (LLY) said it will acquire the clinical-stage biotechnology firm for up to $3.8 billion. Lilly has agreed to pay $6.75 a share in cash upfront ($2.8 billion) – with an additional $2.5 a share in contingent value rights (CVRs) tied to critical clinical and regulatory milestones.

invezz.com - 2026-07-16 13:58:27

CNBC pharma reporter Angelica Peebles broke down the biggest psychedelics deal in Big Pharma history on July 16, 2026.

247wallst.com - 2026-07-16 13:53:41

Eli Lilly and Co (NYSE:LLY) on Thursday agreed to acquire AtaiBeckley Inc. (NASDAQ:ATAI) in a deal that values the clinical-stage mental health biotechnology company at up to approximately $3.8 billion, strengthening Lilly's portfolio of rapid-acting therapies for treatment-resistant depression and other psychiatric disorders.

benzinga.com - 2026-07-16 12:35:53

MILWAUKEE, July 16, 2026 /PRNewswire/ -- Ademi LLP is investigating AtaiBeckley (Nasdaq: ATAI) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Eli Lilly. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.

prnewswire.com - 2026-07-16 12:03:00

The Dow and Russell 2000 are higher today, while the S&P 500 and Nasdaq move lower alongside chip stocks

schaeffersresearch.com - 2026-07-16 11:58:00

AtaiBeckley stock surges after a Bloomberg report said Eli Lilly is in talks for a potential acquisition of the company, as investors await details of the deal.

zacks.com - 2026-07-16 10:55:19

BALA CYNWYD, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.

globenewswire.com - 2026-07-16 10:26:00

Eli Lilly & Co. agreed to buy AtaiBeckley Inc. for as much as $3.8 billion, underscoring growing interest from large drugmakers in psychedelic medicine. Madison Muller has more on "Bloomberg Open Interest.

youtube.com - 2026-07-16 10:23:01

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of AtaiBeckley Inc. (NASDAQ: ATAI) to Eli Lilly and Company for $6.75 per share in cash, plus up to $2.50 per share in the form of a Contingent Value Right entitling the holder to additional cash payments upon achievement of specified development and regulatory milestones related to the BPL-003 and VLS-01 programs.Halper Sadeh encourages AtaiBeckley shareholders to click here to learn more about t.

businesswire.com - 2026-07-16 09:30:00

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has agreed to be acquired by Eli Lilly and Co (NYSE:LLY) in a transaction valued at up to approximately $3.8 billion, with the deal adding the clinical-stage biotechnology company's pipeline of investigational therapies for treatment-resistant depression and other mental health conditions to Lilly's neuroscience portfolio. Under the terms of the agreement, Lilly will pay $6.75 per share in cash at closing, representing an aggregate equity value of about $2.8 billion.

proactiveinvestors.com - 2026-07-16 08:52:52

Wall Street looked set for a mixed open Thursday with further yo-yoing in technology stocks amidst a fresh batch of corporate earnings. Futures pointed to the Dow Jones opening 0.2%, while the S&P 500 was called down 0.2% and the Nasdaq looked set to bear the brunt of the selling, with futures off 0.8% as semiconductor stocks see pressure.

proactiveinvestors.com - 2026-07-16 08:21:34

11:50am: AI stocks out of favor Investors are still favoring stocks with little direct exposure to AI, according to Chris Beauchamp, Chief Market Analyst at...

proactiveinvestors.com - 2026-07-16 07:53:00

Eli Lilly has struck a deal to buy mental-health-focused AtaiBeckley for an initial $2.8 billion, continuing the drugmaker's recent buying spree.

wsj.com - 2026-07-16 07:23:00

Eli Lilly ​said on ‌Thursday it would ​acquire ​psychedelic drug developer ⁠AtaiBeckley ​for up ​to $3.8 billion, entering the ​race ​to develop psychedelic ‌treatments ⁠for depression and other ​mental ​health ⁠disorders.

reuters.com - 2026-07-16 06:50:19

Eli Lilly will acquire psychedelic drugmaker AtaiBeckley for $2.8 billion. AtaiBeckley is developing several psychedelics for mental health conditions.

cnbc.com - 2026-07-16 06:45:53

AtaiBeckley's lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression Acquisition expands Lilly's neuroscience pipeline to address some of the most challenging conditions in mental health INDIANAPOLIS and NEW YORK, July 16, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and AtaiBeckley Inc. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing innovative therapeutics for mental health conditions, today announced a definitive agreement for Lilly to acquire AtaiBeckley. AtaiBeckley is advancing a pipeline of rapid-acting neuroplastogens, including multiple clinical-stage programs and a discovery pipeline of next-generation compounds.

prnewswire.com - 2026-07-16 06:45:00

AtaiBeckley shares soared 50% premarket on Thursday after a report that Eli Lilly was in talks to acquire the psychedelic ​drug developer as soon as this week.

reuters.com - 2026-07-16 06:36:01

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has agreed to be acquired by Eli Lilly and Co (NYSE:LLY) in a transaction valued at up to approximately $3.8...

proactiveinvestors.com - 2026-07-16 04:41:00

Eli Lilly is ​in talks ‌to acquire psychedelic drugmaker AtaiBeckley , ​and ​a deal could ⁠be announced ​as soon ​as this week, Bloomberg News reported ​on ​Wednesday, citing people familiar ‌with ⁠the matter.

reuters.com - 2026-07-15 19:08:30

Psychedelic drug developers including AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Compass Pathways (NASDAQ:CMPS) and Cybin Inc. (NYSE-A:CYBN, FRA:R7E) could...

proactiveinvestors.com - 2026-07-15 11:34:00

Here is how AtaiBeckley Inc (ATAI) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.

zacks.com - 2026-07-14 10:40:17

CleanSpark Inc (NASDAQ:CLSK) shares surged more than 12% after the company announced a 20-year lease agreement for its Sandersville, Georgia data center...

proactiveinvestors.com - 2026-07-14 07:53:00

Tower Semiconductor (NASDAQ:TSEM) shares rose 13% on Tuesday after the company announced a strategic expansion of its silicon photonics, silicon germanium...

proactiveinvestors.com - 2026-07-14 07:20:00

The US Food and Drug Administration's finalized guidance on psychedelic drug development signals the agency remains receptive to helping developers navigate the approval process, a development that Jefferies said could benefit companies including Compass Pathways (NASDAQ:CMPS), AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC), Cybin Inc. (NYSE-A:CYBN, FRA:R7E), GH Research (NASDAQ:GHRS), Awakn Life Sciences (NEO:AWKN) and others in the sector. The firm wrote on Monday that the final guidance, alongside the FDA's plans to hold a public hearing on September 14, points to a more supportive regulatory environment that could reduce regulatory risk for psychedelic drug developers.

proactiveinvestors.com - 2026-07-13 15:18:27

This disposal of 100,000 shares was executed at $4.96 per share, generating gross proceeds of $496,000 on July 7, 2026. The transaction reduced Hershberg direct equity position by 50% through the sale of shares in the open market.

fool.com - 2026-07-09 19:52:13

FuelCell Energy (NASDAQ:FCEL) shares declined on Wednesday after the company priced an upsized public offering of common stock, raising concerns among...

proactiveinvestors.com - 2026-07-08 07:51:00

10am: Wall Street starts in the red Wall Street stocks have mostly opened in the red, after government bond yields climbed to around a seven-week high...

proactiveinvestors.com - 2026-07-08 06:00:00

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) could see increased investor attention as it approaches Phase IIb data for its oral DMT-based therapy VLS-01, according to Jefferies analysts, who highlighted the program's potential to add value to the company's psychedelic medicine pipeline. The analysts wrote that VLS-01's completed Phase IIb enrollment in treatment-resistant depression (TRD) sets up a fourth quarter 2026 topline data readout, which could serve as a potential de-risking event for the program.

proactiveinvestors.com - 2026-07-07 12:56:50

SharkNinja Inc (NYSE:SN.) received a higher price target from Bank of America, which raised its price objective to $165 from $145 and reiterated its 'Buy'...

proactiveinvestors.com - 2026-07-07 11:29:00

ATAI completes dosing in the phase IIb Elumina study of VLS-01 for treatment-resistant depression, with top-line efficacy and safety data due in fourth-quarter 2026.

zacks.com - 2026-07-07 11:10:44

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) could see increased investor attention as it approaches Phase IIb data for its oral DMT-based therapy VLS-01,...

proactiveinvestors.com - 2026-07-07 08:47:00

Lockheed Martin Corp (NYSE:LMT) said on Monday it has signed a definitive agreement to acquire Ultra Maritime for $3.45 billion, in a move aimed at...

proactiveinvestors.com - 2026-07-06 09:28:00

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) said on Monday that it has completed dosing the final patient in its Phase 2b Elumina clinical trial evaluating investigational therapy VLS-01 for adults with treatment-resistant depression (TRD), with topline results expected in the fourth quarter of 2026. The randomized, double-blind, placebo-controlled trial enrolled 156 patients across multiple centers.

proactiveinvestors.com - 2026-07-06 08:43:57

156 patients randomized in multi-center, double-blind, placebo-controlled Phase 2b Elumina trial; topline data anticipated in Q4 2026 (ClinicalTrials.gov: NCT06524830) AtaiBeckley plans to advance VLS-01 into major depressive disorder (MDD) in Phase 3, with generalized anxiety disorder (GAD) as a potential follow-on indication VLS-01 and BPL-003 (in Phase 3 development for treatment-resistant depression with Breakthrough Therapy Designation) together positioned to address patients across the spectrum of mood and anxiety disorders NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that the last patient has been dosed in Elumina, its Phase 2b clinical trial evaluating VLS-01 in adults living with treatment-resistant depression (TRD). The study randomized 156 patients, with topline data expected in Q4 2026.

globenewswire.com - 2026-07-06 06:00:00

ATAI's 2026 rally has raised expectations as key pipeline milestones approach, leaving the stock's outlook increasingly tied to clinical execution and upcoming data.

zacks.com - 2026-07-02 12:30:19

ATAI is pursuing rapid-acting mental health treatments with key late-stage catalysts ahead, but its outlook still hinges on clinical execution and pipeline progress.

zacks.com - 2026-07-02 12:10:25

ATAI enters a catalyst-heavy 2026 as BPL-003 advances toward phase III, with upcoming pipeline milestones set to shape the clinical-stage biotech's outlook.

zacks.com - 2026-07-02 11:51:07

ATAI is now a more focused psychedelics biotech. Particularly, BPL-003 is their main bet on TRD's sizeable TAM. BPL-003 has aligned its research with the FDA's feedback and will proceed with a two-study Phase 3 trial. We'll see its topline readouts by early 2029. ATAI also has VLS-01, which gives it a nearer-term Q4 2026 TRD catalyst. EMP-01 adds some optionality in social anxiety disorders as well.

seekingalpha.com - 2026-06-30 23:09:18

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) announced on Thursday that it will be added to the Russell 2000 Index and the Russell 3000 Index, effective at the open of US markets on June 29, as part of the 2026 Russell indexes reconstitution. The clinical-stage biotechnology company said the inclusion broadens its exposure to institutional investors and index-tracking funds.

proactiveinvestors.com - 2026-06-25 09:05:14

Blackberry (TSX:BB) shares jumped nearly 21% on Thursday in New York and Toronto after the Canadian technology company posted first-quarter fiscal 2027...

proactiveinvestors.com - 2026-06-25 07:57:00

AtaiBeckley to be added to the Russell 2000® Index and the broad-market Russell 3000® Index as part of 2026 reconstitution The Russell U.S. Indexes have approximately $12.2 trillion in assets benchmarked Inclusion expands AtaiBeckley's visibility across U.S. equity markets following recent additions to the S&P Total Market Index, S&P Completion Index, and CRSP® U.S. benchmark indexes in March 2026 NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that it will be added to the Russell 2000® Index and the broad-market Russell 3000® Index, effective at the open of U.S. markets on June 29th as part of the first 2026 Russell indexes reconstitution. Approximately $12.2 trillion in assets are benchmarked against the Russell U.S. indexes, making it one of the most widely referenced index systems for institutional investors, index-tracking funds and active investment strategies.

globenewswire.com - 2026-06-25 06:00:00

Nike Inc (NYSE:NKE, XETRA:NKE) is leaning on its football division to sustain the brand's ongoing turnaround, positioning the category as the next major...

proactiveinvestors.com - 2026-06-05 07:54:00

A stronger-than-expected US labor market report for May calmed fears of an economic slowdown but unsettled financial markets, with Treasury yields surging,...

proactiveinvestors.com - 2026-06-05 07:13:00

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has kept Jefferies analysts bullish on the company following a fireside chat in New York City, with the firm reiterating a 'Buy' rating and a $10 price target on the company, implying roughly 120% upside from current levels. The firm's outlook centers on strengthening late-stage visibility across the company's psychedelic pipeline and what it described as an increasingly constructive regulatory backdrop.

proactiveinvestors.com - 2026-06-04 13:41:48

MYR Group Inc. (NASDAQ:MYRG) has agreed to acquire all outstanding capital stock of Valley Holdings Inc and its subsidiaries, including Valley Electric...

proactiveinvestors.com - 2026-05-28 10:49:00

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has announced the launch of a new Patient Impact Grant Program aimed at supporting non-profit organizations working to improve mental health outcomes through community initiatives, education and research. The clinical-stage biotechnology company said the program will award three grants of $20,000 each to mission-driven organizations focused on advancing mental health support and patient outcomes.

proactiveinvestors.com - 2026-05-28 09:58:38

Three $20,000 grants open to non-profit, mission-driven organizations working across community support, education and stigma reduction, and ecosystem innovation and independent research NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced the launch of its Patient Impact Grant Program, which will award three grants of $20,000 each to non-profit, mission-driven organizations improving mental health outcomes through community leadership, education, and innovative research. Grant Funding Areas Community Support: Organizations who support equitable access to existing and emerging mental health treatments.

globenewswire.com - 2026-05-28 09:00:00

11:55am: Balancing act Gina Bolvin, President of Bolvin Wealth Management Group, said today’s economic data underscores a “tougher balancing act” for...

proactiveinvestors.com - 2026-05-28 07:56:00

NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that members of the Company's management team will participate in multiple upcoming investor conferences in June 2026.

globenewswire.com - 2026-05-27 06:00:00